+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diabetes Drug Market, Oral, Injection, Regions, and Companies

  • ID: 4675451
  • Report
  • November 2018
  • Region: Global
  • 215 Pages
  • Renub Research
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now
The Global Diabetes Drug Market is Expected to Surpass US$ 76 Billion by the End of Year 2024

FEATURED COMPANIES

  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly
  • Johnson & Johnson
  • Merck & Co
  • Novo Nordisk
  • MORE

Global diabetes drug market is expected to surpass US$ 76 Billion by the end of the year 2024. Rising global diabetes prevalence like Type 1 diabetes and Type 2 diabetes is the major reason for the growth of the diabetes drug market. Type 2 diabetes is on the rise globally due to growth in obesity trends, sedentary lifestyle and lack of physical activity. Type1 diabetes patient requires less amount diabetes drug, whereas Type 2 diabetes patient is a massive consumer of diabetes drug. Several companies are creating their diabetes drug pipeline and trying to broaden their diabetes drug portfolio which will further boost the global diabetes drug market in the forecast period.

Diabetes is a condition in which the patient has a high blood sugar level over a long drawn period. There are 3 types of diabetes Type 1 diabetes, Type 2 diabetes, and Gestational diabetes. Type 1 diabetes is a condition in which patient pancreas fails to produce enough insulin. It is also called juvenile diabetes. In Type 2 diabetes body cells fail to respond to insulin properly. The third one is Gestational diabetes in which a pregnant woman with no history of diabetes develops high blood sugar level. Globally 90% of the diabetes patients are Type 2 and rest are Type 1 cases.

This report titled “Diabetes Drug Market, Oral (DPP IV Inhibitor, SGLT-2, Alpha-Glucosidase Inhibitor, Biguanide) Injection (Glucagon-like peptide (GLP) 1 agonist, Amylin Receptor Agonist), Insulin (Rapid - Acting Insulin, Long Acting Insulin, Premixed Insulin), Regions (United States, Europe, Japan, China, India, Brazil), Companies (Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson, Boehringer Ingelheim)” provides a complete analysis of Diabetes Drug Market.

Type 2 Diabetes Patients has bigger Consumer Base

In this report, we have categorized the diabetes drug market into two part; type 1 diabetes drug market and type 2 diabetes drug markets.

(DPP) IV Inhibitor Segment has the largest Market in Global Diabetes Drug Market

According to this research, this report provides an in-depth analysis of diabetes drug market form multiple perspectives. Here the global diabetes drug market has been categorized into 3 segments: Oral

Diabetes Drug Market, Injectable Diabetes Drug Market, and Insulin

  • Oral Diabetes Drug Market is further sub-divided into 5 categories by drug class- (DPP) IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide, and Other Oral Drug markets.
  • Injectable Diabetes Drug Market has been further classified into 2 parts - Glucagon-like peptide (GLP) 1 agonist and Amylin receptor agonist market.
  • Insulin Market has been further categorized into 4 parts - Rapid - Acting Insulin market, Long Acting Insulin market, Premixed Insulin market, and Other Insulin markets.

United States dominates the Global diabetes drug Market

The regions covered in the report for of type 1 diabetes drug market are the United States, European Union (France, Germany, Italy, Spain and United Kingdom), Japan and Canada.

The regions covered for type 2 diabetes drug market - are United States, European Union (France, Germany, Italy, Spain and United Kingdom), Japan, China, India and Brazil. In addition, we have also covered diabetes population of each of these covered regions along with Type 1 and Type 2 diabetes populations.

Novo Nordisk is the Largest Player in Global Diabetes Drug Market

In this report, a comprehensive assessment of global diabetes drug revenue by five major key players is covered. The key players covered in the report are Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson and Boehringer Ingelheim. This report covers historical sales analysis and forecast along with major factors like diabetes R&D and pipeline of diabetes drug in a separate chapter.

Disease Type - Global Diabetes Drug Market

1. By Type 1 Diabetes Drug Market
2. By Type 2 Diabetes Drug Market

Product - Global Diabetes Drug Market

Oral

1. (DPP) IV inhibitor
2. SGLT-2
3. Alpha Glucosidase Inhibitor
4. Biguanide
5. Others Oral Drug

Injection

1. Glucagon-like peptide (GLP) 1 agonist
2. Amylin receptor agonist

Insulin

1. Rapid - Acting Insulin
2. Long-Acting Insulin
3. Premixed Insulin
4. Other Insulin

Regions - Population Type 1 & Type 2 Diabetes Drug

1. United States
2. 5 European Union (France, Germany, Italy, Spain and United Kingdom)
3. Japan
4. China
5. India
6. Brazil

Regions - Type 1 Diabetes Drug Market

1. United States
2. 5 European Union (France, Germany, Italy, Spain and United Kingdom)
3. Japan
4. Canada

Regions - Type 2 Diabetes Drug Market

1. United States
2. 5 European Union (France, Germany, Italy, Spain and United Kingdom)
3. Japan
4. China
5. India
6. Brazil

Key Players Analysis

1. Novo Nordisk
2. Merck & Co
3. Eli Lilly
4. AstraZeneca
5. Johnson & Johnson
6. Boehringer Ingelheim

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly
  • Johnson & Johnson
  • Merck & Co
  • Novo Nordisk
  • MORE

1. Introduction
1.1 Market Definition
1.2 Currency Conversion

2. Research Methodology

3. Executive Summary

4. Global Diabetes Drug Market

5. Market Share - Global Diabetes Drug
5.1 Disease Type
5.2 Therapy - (Oral, Injection, Insulin)
5.3 Oral Drug
5.4 Injection Drug
5.5 Insulin
5.6 Regions - Type 1 Diabetes Drug
5.7 Regions - Type 2 Diabetes Drug

6. Disease Type - Global Diabetes Drug Market
6.1 Type 1 Diabetes
6.2 Type 2 Diabetes

7. Therapy - Global Diabetes Drug Market
7.1 Oral Drugs Market
7.1.1 (DPP) IV Inhibitor
7.1.2 SGLT-2
7.1.3 Alpha Glucosidase Inhibitor
7.1.4 Biguanide
7.1.5 Others Oral Drug
7.2 Injectable Drugs Market
7.2.1 Glucagon-like peptide (GLP) 1 agonist
7.2.2 Amylin Receptor Agonist
7.3 Insulin Market
7.3.1 Rapid - Acting Insulin
7.3.2 Long Acting Insulin
7.3.3 Premixed Insulin
7.3.4 Other Insulin

8. Region - Type 1 Diabetes Drug Market
8.1 United States
8.2 European Union
8.3 Japan
8.4 Canada

9. Region - Type 2 Diabetes Drug Market
9.1 United States
9.2 European Union
9.3 Japan
9.4 China
9.5 India
9.6 Brazil

10. Regions - Diabetic Population
10.1 United States
10.1.1 Type 1
10.1.2 Type 2
10.2 European Union
10.2.1 Type 1
10.2.2 Type 2
10.3 Japan
10.3.1 Type 1
10.3.2 Type 2
10.4 Canada
10.4.1 Type 1
10.4.2 Type 2
10.5 China
10.5.1 Type 2
10.6 India
10.6.1 Type 2
10.7 Brazil
10.7.1 Type 2

11. Key Players Analysis
11.1 Novo Nordisk Overview
11.1.1 R&D Pipeline
11.1.2 Sales Analysis
11.2 Merck & Co Overview
11.2.1 R&D Pipeline
11.2.2 Sales Analysis
11.3 Eli Lilly Overview
11.3.1 R&D Pipeline
11.3.2 Sales Analysis
11.4 AstraZeneca Overview
11.4.1 R&D Pipeline
11.4.2 Sales Analysis
11.5 Johnson & Johnson Overview
11.5.1 R&D Pipeline
11.5.2 Sales Analysis
11.6 Boehringer Ingelheim Overview
11.6.1 R&D Pipeline
11.6.2 Sales Analysis

12. Mergers & Acquisitions

13. Market Dynamics
13.1 Growth Drivers
13.1.1 Rising Prevalence of Diabetes
13.1.2 Rising Cost of Diabetes Care
13.2 Challenges
13.2.1 Controversy regarding Clinical Benefits
13.3 Opportunities

List of Figures:
Figure-01: Global - Diabetes Drugs Market size (Million US$), 2018 & 2024
Figure-02: Global - Diabetes Drugs Growing Segments
Figure-03: Global - Diabetes Drugs Market (Million US$), 2016 - 2017
Figure-04: Global - Forecast for Diabetes Drugs Market(Million US$), 2018 - 2024
Figure-05: Global - Diabetes Drugs Market Share by Disease type (Percent), 2016 - 2017
Figure-06: Global - Forecast for Diabetes Drugs Market Share by disease type(Percent), 2018 - 2024
Figure-07: Global - Diabetes Drugs Market Share by Therapy (Percent), 2016 - 2017
Figure-08: Global - Forecast for Diabetes Drugs Market Share by Therapy (Percent), 2018 - 2024
Figure-09: Global - Diabetes Drugs Market Share by Oral Drug (Percent), 2016 - 2017
Figure-10: Global - Forecast for Diabetes Drugs Market Share by Oral Drug (Percent), 2018 - 2024
Figure-11: Global - Diabetes Drugs Market Share by Injectable Drug (Percent), 2016 - 2017
Figure-12: Global - Forecast for Diabetes Drugs Market Share by Injectable Drug (Percent), 2018 - 2024
Figure-13: Global - Diabetes Drugs Market Share by Insulin (Percent), 2016 - 2017
Figure-14: Global - Forecast for Diabetes Drugs Market Share by Insulin (Percent), 2018 - 2024
Figure-15: Global - Diabetes Drugs Market Share type1 Diabetes Drug by Regions (Percent), 2016 - 2017
Figure-16: Global - Forecast for Diabetes Drugs Market Share type1 Diabetes Drug by Regions (Percent), 2018 - 2024
Figure-17: Global - Diabetes Drugs Market Share type2 Diabetes Drug by Regions (Percent), 2016 - 2017
Figure-18: Global - Forecast for Diabetes Drugs Market Share type2 Diabetes Drug by Regions (Percent), 2018 - 2024
Figure-19: Global - Diabetes Drug Market by type1 Diabetes (Million US$), 2016 - 2017
Figure-20: Global - Forecast for Diabetes Drug Market by type1 Diabetes (Million US$), 2018 - 2024
Figure-21: Global - Diabetes Drug Market by type2 Diabetes (Million US$), 2016 - 2017
Figure-22: Global - Forecast for Diabetes Drug Market by type2 Diabetes (Million US$), 2018 - 2024
Figure-23: Global - Oral Drug (DPP) IV inhibitor Market (Million US$), 2016 - 2017
Figure-24: Global - Forecast for Oral Drug (DPP) IV inhibitor Market (Million US$), 2018 - 2024
Figure-25: Global - Oral Drug SGLT-2 Market (Million US$), 2016 - 2017
Figure-26: Global - Forecast for Oral Drug SGLT-2 Market (Million US$), 2018 - 2024
Figure-27: Global - Oral Drug Alpha Glucosidase Inhibitor Market (Million US$), 2016 - 2017
Figure-28: Global - Forecast for Oral Drug Alpha glucosidase inhibitor Market (Million US$), 2018 - 2024
Figure-29: Global - Oral Drug Biguanide Market (Million US$), 2016 - 2017
Figure-30: Global - Forecast for Oral Drug Biguanide Market (Million US$), 2018 - 2024
Figure-31: Global - Oral Drug Others Market (Million US$), 2016 - 2017
Figure-32: Global - Forecast for Oral Drug Others Market (Million US$), 2018 - 2024
Figure-33: Global - Diabetes Injectable Drug Glucagon-like peptide (GLP) 1 agonist Market (Million US$), 2016 - 2017
Figure-34: Global - Forecast for Diabetes Injectable Drug Glucagon-like peptide (GLP) 1 agonist Market (Million US$), 2018 - 2024
Figure-35: Global - Diabetes Injectable Drug Amylin receptor agonist Market (Million US$), 2016 - 2017
Figure-36: Global - Forecast for Diabetes Injectable Drug Amylin receptor agonist Market (Million US$), 2018 - 2024
Figure-37: Global - Diabetes Insulin Drug Rapid Acting (Fast Acting) Market (Million US$), 2016 - 2017
Figure-38: Global - Forecast for Diabetes Insulin Drug Rapid Acting (Fast Acting) Market (Million US$), 2018 - 2024
Figure-39: Global - Diabetes Insulin Drug Long Acting Market (Million US$), 2016 - 2017
Figure-40: Global - Forecast for Diabetes Insulin Drug Long Acting Market (Million US$), 2018 - 2024
Figure-41: Global - Diabetes Insulin Drug Premixed Market (Million US$), 2016 - 2017
Figure-42: Global - Forecast for Diabetes Insulin Drug Premixed Market (Million US$), 2018 - 2024
Figure-43: Global - Diabetes Drug Other Insulin (Including Human Insulin) Market (Million US$), 2016 - 2017
Figure-44: Global - Forecast for Diabetes Drug Other Insulin (Including Human Insulin) Market (Million US$), 2018 - 2024
Figure-45: United States - type1 Diabetes Drug Market (Million US$), 2016 - 2017
Figure-46: United States - Forecast for Type1 Diabetes Drug Market (Million US$), 2018 - 2024
Figure-47: 5 European Union - type 1 Diabetes Drug Market (Million US$), 2016 - 2017
Figure-48: 5 European Union - Forecast for type 1 Diabetes Drug Market (Million US$), 2018 - 2024
Figure-49: Japan - type1 Diabetes Drug Market (Million US$), 2016 - 2017
Figure-50: Japan - Forecast for type1 Diabetes Drug Market (Million US$), 2018 - 2024
Figure-51: Canada - type 1 Diabetes Drug Market (Million US$), 2016 - 2017
Figure-52: Canada - Forecast for type1 Diabetes Drug Market (Million US$), 2018 - 2024
Figure-53: United States - type2 Diabetes Drug Market (Million US$), 2016 - 2017
Figure-54: United States - Forecast for type2 Diabetes Drug Market (Million US$), 2018 - 2024
Figure-55: 5 European Union - type2 Diabetes Drug Market (Million US$), 2016 - 2017
Figure-56: 5 European Union - Forecast for type2 Diabetes Drug Market (Million US$), 2018 - 2024
Figure-57: Japan - type2 Diabetes Drug Market (Million US$), 2016 - 2017
Figure-58: Japan - Forecast for type2 Diabetes Drug Market (Million US$), 2018 - 2024
Figure-59: China - type2 Diabetes Drug Market (Million US$), 2016 - 2017
Figure-60: China - Forecast for type2 Diabetes Drug Market (Million US$), 2018 - 2024
Figure-61: India - type2 Diabetes Drug Market (Million US$), 2016 - 2017
Figure-62: India - Forecast for type2 Diabetes Drug Market (Million US$), 2018 - 2024
Figure-63: Brazil - type2 Diabetes Drug Market (Million US$), 2016 - 2017
Figure-64: Brazil - Forecast for type2 Diabetes Drug Market (Million US$), 2018 - 2024
Figure-65: United States - Diabetes Population (Thousands), 2010 - 2017
Figure-66: United States - Forecast for Diabetes Population (Thousands), 2018 - 2024
Figure-67: United States - type1 Diabetes Population (Thousands), 2010 - 2017
Figure-68: United States - Forecast for type1 Diabetes Population (Thousands), 2018 - 2024
Figure-69: United States - type2 Diabetes Population (Thousands), 2010 - 2017
Figure-70: United States - Forecast for type2 Diabetes Population (Thousands), 2018 - 2024
Figure-71: European Union - Diabetes Population (Thousands), 2010 - 2017
Figure-72: European Union - Forecast for Diabetes Population (Thousands), 2018 - 2024
Figure-73: 5 European Union - type1 Diabetes Population (Thousands), 2010 - 2017
Figure-74: 5 European Union - Forecast for type1 Diabetes Population (Thousands), 2018 - 2024
Figure-75: European Union - type2 Diabetes Population (Thousands), 2010 - 2017
Figure-76: European Union - Forecast for type2 Diabetes Population (Thousands), 2018 - 2024
Figure-77: Japan - Diabetes Population (Thousands), 2010 - 2017
Figure-78: Japan - Forecast for Diabetes Population (Thousands), 2018 - 2024
Figure-79: Japan - Type1 Diabetes Population (Thousands), 2010 - 2017
Figure-80: Japan - Forecast for type1 Diabetes Population (Thousands), 2018 - 2024
Figure-81: Japan - Type2 Diabetes Population (Thousands), 2010 - 2017
Figure-82: Japan - Forecast for Type2 Diabetes Population (Thousands), 2018 - 2024
Figure-83: Canada - Diabetes Population (Thousands), 2010 - 2017
Figure-84: Canada - Forecast for Diabetes Population (Thousands), 2018 - 2024
Figure-85: Canada - type1 Diabetes Population (Thousands), 2010 - 2017
Figure-86: Canada - Forecast for type1 Diabetes Population (Thousands), 2018 - 2024
Figure-87: China - type2 Diabetes Population (Thousands), 2010 - 2017
Figure-88: China - Forecast for type2 Diabetes Population (Thousands), 2018 - 2024
Figure-89: India - type2 Diabetes Population (Thousands), 2010 - 2017
Figure-90: India - Forecast for type2 Diabetes Population (Thousands), 2018 - 2024
Figure-91: Brazil - Diabetes Population (Thousands), 2010 - 2017
Figure-92: Brazil - Forecast for Diabetes Population (Thousands), 2018 - 2024
Figure-93: Global - Novo Nordisk Diabetes Drug Sales (Million US$), 2015 - 2017
Figure-94: Global - Forecast for Novo Nordisk Diabetes Drug Sales (Million US$), 2018 - 2024
Figure-95: Global - Merck & Co Diabetes Drug Sales (Million US$), 2015 - 2017
Figure-96: Global - Forecast for Merck & Co Diabetes Drug Sales (Million US$), 2018 - 2024
Figure-97: Global - Eli Lilly Diabetes Drug Sales (Million US$), 2015 - 2017
Figure-98: Global - Forecast for Eli Lilly Diabetes Drug Sales (Million US$), 2018 - 2024
Figure-99: Global - AstraZeneca Diabetes Drug Sales (Million US$), 2015 - 2017
Figure-100: Global - Forecast for AstraZeneca Diabetes Drug Sales (Million US$), 2018 - 2024
Figure-101: Global - Johnson & Johnson Diabetes Drug Sales (Million US$), 2015 - 2017
Figure-102: Global - Forecast for Johnson & Johnson Diabetes Drug Sales (Million US$), 2018 - 2024
Figure-103: Global - Boehringer Ingelheim Diabetes Drug Sales (Million US$), 2015 - 2017
Figure-104: Global - Forecast for Boehringer Ingelheim Diabetes Drug Sales (Million US$), 2018 - 2024

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly
  • Johnson & Johnson
  • Merck & Co
  • Novo Nordisk
Note: Product cover images may vary from those shown
5 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll